{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:54:22Z","timestamp":1781506462623,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":8,"publisher":"Springer US","isbn-type":[{"value":"9781071648100","type":"print"},{"value":"9781071648117","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-4811-7_16","type":"book-chapter","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:50:34Z","timestamp":1759276234000},"page":"251-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intramuscular and Intravenous AAV-Mediated Gene Delivery in Mouse Models"],"prefix":"10.1007","author":[{"given":"Liubov V.","family":"Gushchina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"3685","key":"16_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.149.3685.754","volume":"149","author":"RW Atchison","year":"1965","unstructured":"Atchison RW, Casto BC, Hammon WM (1965) Adenovirus-associated defective virus particles. Science 149(3685):754\u2013756","journal-title":"Science"},{"key":"16_CR2","doi-asserted-by":"crossref","unstructured":"Zwi-Dantsis L et al (2025) Adeno-associated virus vectors: principles, practices, and prospects in gene therapy. Viruses 17(2)","DOI":"10.3390\/v17020239"},{"issue":"11","key":"16_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.nmd.2015.08.005","volume":"25","author":"A Vulin","year":"2015","unstructured":"Vulin A et al (2015) The first exon duplication mouse model of Duchenne muscular dystrophy: a tool for therapeutic development. Neuromuscul Disord 25(11):827\u2013834","journal-title":"Neuromuscul Disord"},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","volume":"21","author":"TR Simmons","year":"2021","unstructured":"Simmons TR et al (2021) Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping. Mol Ther Methods Clin Dev 21:325\u2013340","journal-title":"Mol Ther Methods Clin Dev"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.omtm.2022.07.005","volume":"26","author":"N Wein","year":"2022","unstructured":"Wein N et al (2022) Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev 26:279\u2013293","journal-title":"Mol Ther Methods Clin Dev"},{"key":"16_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101144","volume":"31","author":"LV Gushchina","year":"2023","unstructured":"Gushchina LV et al (2023) Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model. Mol Ther Methods Clin Dev 31:101144","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"16_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1):23\u201336","journal-title":"Blood"},{"key":"16_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ (2022) Immunogenicity and toxicity of AAV gene therapy. Front Immunol 13:975803","journal-title":"Front Immunol"}],"container-title":["Methods in Molecular Biology","Duchenne Muscular Dystrophy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4811-7_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:32:46Z","timestamp":1781505166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4811-7_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"ISBN":["9781071648100","9781071648117"],"references-count":8,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4811-7_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"1 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}